IAMBIC THERAPEUTICS, INC.

INDEMNIFICATION AGREEMENT

This Indemnification Agreement (this “Agreement”) is dated as of [insert date], and is between Iambic Therapeutics, Inc., a Delaware corporation (the “Company”), and [insert name of indemnitee] (“Indemnitee”).

RECITALS

A. Indemnitee’s service to the Company substantially benefits the Company.

B. Individuals are reluctant to serve as directors or officers of corporations or in certain other capacities unless they are provided with adequate protection through insurance or indemnification against the risks of claims and actions against them arising out of such service.

C. Indemnitee does not regard the protection currently provided by applicable law, the Company’s governing documents and any insurance as adequate under the present circumstances, and Indemnitee may not be willing to serve as a director or officer without additional protection.

…

IAMBIC THERAPEUTICS, INC.

CHANGE IN CONTROL AND SEVERANCE PLAN

AND SUMMARY PLAN DESCRIPTION

1. Introduction. The purpose of this Iambic Therapeutics, Inc. Change in Control and Severance Plan (the “Plan”) is to provide assurances of specified benefits to certain employees of the Company whose employment could be being involuntarily terminated under the circumstances described in the Plan. This Plan is adopted by the Board effective as of the Effective Date, and upon the Effective Date, this Plan will supersede any severance benefits which may be available to a Participant under an individual agreement between any member of the Company Group and the Participant which is in effect as of the Effective Date. This Plan is an “employee welfare benefit plan,” as defined in Section 3(1) of ERISA. This document is both the written instrument under which the Plan is maintained and the required summary plan description for the Plan.

…

Exhibit10.8

Iambic Therapeutics, Inc.

Confirmatory Executive Offer Letter

September 18, 2026

Michael Secora

Dear Dr. Secora:

This letter agreement (the “Agreement”) is entered into between Iambic Therapeutics, Inc. (the “Company” or “we”) and you. This Agreement is effective as of the effective date of the first registration statement that is filed by the Company and declared effective pursuant to Section 12(b) of the Exchange Act with respect to the Company’s common stock (the “Effective Date”). The purpose of this Agreement is to confirm the terms and conditions of your continued employment with the Company as of the Effective Date.

1.

…

EMPLOYMENT AGREEMENT

This Employment Agreement (“Agreement”) is made on and effective as of the date signed by the last party to sign on the signature page below.

Between

(1)

IAMBIC THERAPEUTICS UK LTD, incorporated and registered in England and Wales with company number 12789012 whose registered office is at [***] (the “Company”, “we” or “us”); and

(2)

Frederick Manby of [***] (the “Employee” or “you”)

Agreed terms

1.

Interpretation

1.1.

The definitions and rules of interpretation in this clause 1 apply in this Agreement.

“Associated Employer” has the meaning given to it in the Employment Rights Act 1996.

“Board” means the board of directors of Iambic Therapeutics, Inc. (including any committee of the board duly appointed by it).

“Business Day” means a day, other than a Saturday, Sunday or public holiday in England, when banks in London are open for business.

“Employee Handbook” means the Company’s employee handbook (if any) as amended from time to time.

“Employment” means your employment by us on the terms of this Agreement.

…

[***] Certain information in this document has been omitted from this exhibit pursuant to Item 601(b) of Regulation S-K because it is both not material and is the type that the Registrant treats as private or confidential.

Collaboration and Option Agreement

Between

Iambic Therapeutics, Inc.

and

H. Lundbeck A/S

1

---

COLLABORATION AND OPTION AGREEMENT

This COLLABORATION AND OPTION AGREEMENT (the “Agreement”) is entered into as of September 23, 2024 (the “Effective Date”) between Iambic Therapeutics, Inc., a Delaware corporation, having its principal place of business at 5627 Oberlin Drive, Suite 120, San Diego, California 92121 (“Iambic”) and H. Lundbeck A/S, a Danish corporation, having its principal place of business at Ottiliavej 9, 2500 Valby, Denmark (“Lundbeck”). Lundbeck and Iambic each may be referred to herein individually as a “Party” or collectively as the “Parties.” All attached appendices, exhibits and schedules are a part of this Agreement.

RECITALS

…

[***] Certain information in this document has been omitted from this exhibit pursuant to Item 601(b) of Regulation S-K because it is both not material and is the type that the Registrant treats as private or confidential.

RESEARCH COLLABORATION AND LICENSE AGREEMENT

DATED AS OF FEBRUARY 3, 2026

BY AND BETWEEN

IAMBIC THERAPEUTICS, INC.

AND

TAKEDA PHARMACEUTICALS, U.S.A., INC.

---

TABLE OF CONTENTS

ARTICLE 1.	DEFINITIONS	1
ARTICLE 2.	LICENSES; DATA RIGHTS; EXCLUSIVITY	25
2.1	License Grants to Takeda	25
2.2	License Grant to Iambic	25

…

Iambic Therapeutics, Inc.

Confirmatory Executive Offer Letter

September 18, 2026

Thomas Miller

Dear Dr. Miller:

This letter agreement (the “Agreement”) is entered into between Iambic Therapeutics, Inc. (the “Company” or “we”) and you. This Agreement is effective as of the effective date of the first registration statement that is filed by the Company and declared effective pursuant to Section 12(b) of the Exchange Act with respect to the Company’s common stock (the “Effective Date”). The purpose of this Agreement is to confirm the terms and conditions of your continued employment with the Company as of the Effective Date.

1.

…

Execution Version

CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

[***] INDICATES THAT INFORMATION HAS BEEN REDACTED.

SUB-LICENSE AGREEMENT

This SUB-LICENSE AGREEMENT (the “Agreement”), is made and effective as of April 8, 2011 (the “Effective Date”) by NT Life Sciences, LLC, a Delaware limited liability company (“Sublicensor”), Kadmon Pharmaceuticals, LLC, a Delaware limited liability company (“Sublicensee”) and Surface Logix, Inc., a Delaware corporation (“SLX”) (each of SLX, Sublicensor and Sublicensee being a “Party,” and collectively, the “Parties”).

BACKGROUND

A. WHEREAS, Sublicensor has obtained by way of a license agreement (the “Main License Agreement”) dated even date hereof between Sublicensor and SLX, certain intellectual property that SLX owns or has the right to license.

…

FORM OF AMENDED AND RESTATED VOTING AGREEMENT

THIS AMENDED AND RESTATED VOTING AGREEMENT (this “Agreement”) is made and entered into as of April 22, 2025 by and among Retension Pharmaceuticals, Inc., a Delaware corporation (the “Company”), each holder of the Series A Preferred Stock, $0.0001 par value per share, of the Company (the “Series A Preferred Stock”) and each holder of the Series B Preferred Stock, $0.0001 par value per share, of the Company (the “Series B Preferred Stock” and collectively with the Series A Preferred Stock, the “Preferred Stock”) listed on Schedule 1 (together with any subsequent investors, or transferees, who become parties hereto as “Investors” pursuant to Sections 7.1(a) or 7.2 below, the “Investors”), and each holder of Common Stock, $0.0001 par value per share, of the Company (the “Common Stock”) listed on Schedule 2 (together with any subsequent stockholders or option holders or transferees thereof, who become parties hereto as “Key Holders” pursuant to Sections 7.1(b) or 7.2 below, the “Key Holders,” and to

…

RETENSION PHARMACEUTICALS, INC.

** **

INDEMNIFICATION AGREEMENT

This Indemnification Agreement (this “Agreement”), dated as of ________ __, 20__, is made between Retension Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and [______________] (the “Indemnitee”).

RECITALS

WHEREAS, the Company desires to attract and retain the services of talented and experienced individuals, such as Indemnitee, to serve as directors and officers of the Company and its subsidiaries and wishes to indemnify its directors and officers to the maximum extent permitted by law;

WHEREAS, the Company and Indemnitee recognize that corporate litigation subjects directors and officers to expensive litigation risks, and that the amount of time and expense required to resolve such matters often bears no reasonable relationship to the merit of the claims asserted;

…

Execution Version

CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

[***] INDICATES THAT INFORMATION HAS BEEN REDACTED

EXCLUSIVE SUB-LICENSE AGREEMENT FOR KD-026 AND KD-027

This EXCLUSIVE SUB-LICENSE AGREEMENT (this “Agreement”), is made and effective as of February 13, 2019 (the “Effective Date”) by and between Kadmon Corporation, LLC (f/k/a Kadmon Pharmaceuticals, LLC), a Delaware limited liability company with its principal office at 450 East 29th Street, New York, NY 10016 (“Kadmon” or “Sublicensor”) and Redux Therapeutics, LLC, a Massachusetts limited liability company having its principal office at 902 Turkey Run Road, McLean, VA 22101 (“Redux”). Kadmon and Redux each are referred to herein as a “Party” and are referred to together as the “Parties.”

BACKGROUND

…

Termination of Consulting Agreement

This Termination of Consulting Agreement (this “Termination Agreement”) is effective as of the Effective Date (as the term is defined in this Termination Agreement), by and between Retension Pharmaceuticals, Inc., a Delaware corporation (the “Company”) and CRS Capital Ventures I, LLC (“Consultant”, and together with the Company, the “Parties” and each, a “Party”).

WHEREAS, the Company and Advisor entered into that certain Consulting Agreement, dated August 1, 2025 (the “Consulting Agreement”); and

WHEREAS, the Parties desire to correct certain errors in the Consulting Agreement, followed by the termination of the Consulting Agreement as corrected, with such termination being effective as the Effective Date.

NOW THEREFORE, in consideration of the mutual covenants and agreements set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:

1. Acknowledgement of Scrivener’s Errors and Amendments to Consulting Agreement.

…